Can An Off Label Drug Stop Multiple Sclerosis, Help Viral Diseases…and Cancer?

Meet LDN. 

The success of LDN as a therapy or accompanying therapy in M.S., viral diseases and cancer is opening up a whole new arena of understanding as to how these diseases develop.

Let’s look at M.S. Multiple Sclerosis is not a typical autoimmune disease as previously thought but appears to be a cross-immune disease where the antibodies formed against some viruses may be crossing over and attacking myelin in the patients which causes loss of nerve activity, neurotoxicity and plaque development.

All M.S. patients test positive for Epstein Barr Virus (EBV) but not all EBV patients develop M.S. The EBV, however, may be imperative to allow secondary viruses to express themselves.

When secondary viruses are activated, then M.S. is apparently allowed to develop. The reason that the secondary viruses found in M.S. are active may be from the elevation of the Interleukin 10 from the LMP-1 protein, which is elevated from the EBV. IL-10 lowers the TH1 lymphocytes responsible for fighting cancer and viruses.

One of the secondary viruses found (from Professor Zur Hausen) is a circular bovine virus. Others have also found the herpes simplex virus involved in M.S. patients. The IL-10 is a major player in persistent viral infections, including Hepatitis B, C and HIV.

Recent studies in animal models and later humans have shown that low dose naltrexone (LDN) inhibits the neuroactive opioid growth factor (OGF) and alters the blood levels of important pro and anti-inflammatory proteins in multiple sclerosis.

One of the additionally important mechanisms of LDN is its ability to lower IL-10. This helps in both viral infections and cancer as both show an elevation of IL-10 in their progression. The inflammatory parameters also play a role in viral toxicity and in cancer growth. They are also dramatically influenced by LDN.

One of the major effects seen in support of LDN appears to be via the inhibition of OGF receptor and the reduction of pro-inflammatory cytokines. LDN lowers IL-10, which affects the Th-1 lymphocytes responsible for fighting viruses and cancer, therefore raising the immune system to fight these diseases.

LDN is a promising adjuvant for many diseases and may even prove essential as a baseline for improving the efficacies of other therapies for improved M.S., viral and cancer remissions and potentially cures.

Prof (hon). Dr. Dana F. Flavin, Dr. med univ, M.S. www.collmed.org

https://journals.sagepub.com/doi/full/10.1177/2055217316672242

https://www.msnz.org.nz/low-dose-naltrexone-ldn/

https://multiplesclerosisnewstoday.com/2018/02/20/low-dose-naltrexone-changes-levels-inflammatory-proteins-in-ms/

https://www.ncbi.nlm.nih.gov/pubmed/20703965/

https://www.ncbi.nlm.nih.gov/pubmed/28316998/

https://herpesviridae.biomedcentral.com/articles/10.1186/2042-4280-5-1

http://m.jbc.org/content/278/6/3694.full.html